Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steady-state pharmacokinetics of caspofungin in plasma, epithelial lining fluid, and alveolar macrophages in ventilated immunosuppressed ICU patients
2007-000517-10Phase 3Completed
- Sponsor
- Hannover Clinical Trial Center
- Start
- May 2007
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of caspofungin in fungal pneumonia, sponsored by Hannover Clinical Trial Center. Primary endpoint: Steady-state caspofungin concentrations in epithelial lining fluid and alveolar cells. Started May 2007; status: completed.
02
Drugs
caspofungin
03
Conditions
fungal pneumonia
Beyond the preview
Go deeper on 2007-000517-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000517-10.